StockNews.AI
PSTV
StockNews.AI
9 hrs

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

1. Plus Therapeutics signed a deal with UnitedHealthcare for CNSide diagnostics. 2. Agreement covers over 51 million people in the U.S. for tumor testing. 3. CNSide® assay shows high sensitivity (92%) and specificity (95%) in testing. 4. Over 11,000 CNSide tests conducted, influencing treatment decisions in 90% of cases. 5. CNSide Diagnostics enhances patient management for central nervous system tumors.

6m saved
Insight
Article

FAQ

Why Bullish?

The agreement with UnitedHealthcare validates CNSide's market position and potential growth, as seen previously with healthcare collaborations that boosted similar biotech stocks. Historical cases, like those of companies gaining significant traction in partnerships, resulted in positive price movements post-announcement.

How important is it?

The partnership with a major insurer enhances PSTV's credibility and market reach, likely increasing revenues. Moreover, given the scale of the deal, it should positively affect investor sentiment and stock demand.

Why Long Term?

The deal strengthens PSTV's market presence, promising future revenue and improved patient outcomes long-term. This similar situation occurred with other biotech firms that secured nationwide contracts, reflecting sustained growth.

Related Companies

UNHPSTV
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH), effective September 15, 2025, covering over 51 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT). The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use. More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases. This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S. About CNSide Diagnostics, LLC CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.   For more information, visit https://www.cnside-dx.com/. About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com. About UnitedHealthcare GroupUnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.   These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates. Investor ContactCORE IRinvestor@plustherapeutics.com

Related News